The pharma industry has been facing increasing pressure in recent years to adopt eco-friendly practices without compromising product safety or efficacy.
Dr Leeza Osipenko and colleagues analysed the quality of clinical evidence submitted by companies to NICE technology appraisals (TAs) over the last 20 years.
The way HTAs are conducted in Europe is changing. And, if organisations act now to overcome the challenges, they could reap the rewards for years to come.
It’s been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats.
The passage of the Inflation Reduction Act (IRA) signifies more than just a legislative milestone; it acts as a clarion call to the pharmaceutical industry.
Creating healthcare interventions and technological solutions that work is hard enough. But when the goal is sustainable system-wide improvement, it’s the easy part.